Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that nine abstracts have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held from November 7-11, 2018 in Washington, D.C.

Details of Arcus’s poster presentations are as follows.

AB928 (dual A2aR/A2bR antagonist)Title: Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928Poster Number: P35; Abstract ID: 10513Poster Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E

Title: Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity.Poster Number: P668; Abstract ID: 10724Poster Presentation Hours: Saturday, Nov. 10 from 12:20 – 1:50 pm and 7:00 – 8:30 pm ETPoster Hall Location: Hall E

Title: A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with breast or gynecologic malignanciesPoster Number: P320 (Trial in Progress); Abstract ID: 10688Poster Presentation Hours: Saturday, Nov. 10 from 12:20 – 1:50 pm and 7:00 – 8:30 pm ETPoster Hall Location: Hall E

Title: A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with gastrointestinal malignanciesPoster Number: P321 (Trial in Progress); Abstract ID: 10700Poster Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E

Title: A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with carboplatin/pemetrexed and pembrolizumab in lung cancer patientsPoster Number: P322 (Trial in Progress); Abstract ID: 10706Poster Presentation Hours: Saturday, Nov. 10 from 12:20 – 1:50 pm and 7:00 – 8:30 pm ETPoster Hall Location: Hall E

Title: A phase 1 study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, with AB122, a programmed cell death-1 inhibitor, in patients with advanced malignanciesPoster Number: P323 (Trial in Progress); Abstract ID: 10711Poster Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E

AB122 (anti-PD-1 antibody)Title: Preliminary results from an ongoing Phase 1 study of AB122, an anti-programmed cell death-1 (PD-1) monoclonal antibody, in patients with advanced solid tumors.Poster Number: P673; Abstract ID: 10638Poster Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E

Title: Development of a robust, simplified method to measure receptor occupancy in peripheral blood from patients treated with a novel anti-PD1 agent, AB122.Poster Number: P15; Abstract ID: 10495Poster Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E

AB154 (anti-TIGIT antibody)Title: Preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapiesPoster Number: P697; Abstract ID: 10538Poster Presentation Hours: Friday, Nov. 9, from 12:45 – 2:15 pm. and 6:30 – 8 pm ETPoster Hall Location: Hall E

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181002006073/en/

Arcus Biosciences, Inc.Jennifer Jarrett, [e-mail] Arndt, [e-mail]